Sen-Jam Pharmaceutical

Founded in 2018 by Jacqueline Iversen and Jim Iversen, and based in New York, US, Sen-Jam Pharmaceutical operates as a biotechnology platform that provides innovative treatments for inflammation-based diseases using proprietary next-generation anti-inflammatory technologies. In January 2025, Sen-Jam Pharmaceutical raised venture funding led by 5 Horizons Capital. Sen-Jam Pharmaceutical specializes in the development of next-generation anti-inflammatory therapies aimed at addressing a variety of inflammation-related conditions, including viral respiratory infections, arthritis, alcohol hangovers, and opioid withdrawal. Their core product offerings revolve around proprietary combinations of already established molecular agents designed to mitigate inflammation effectively and safely.

Notably, their key products include SJP-002C for mild to moderate COVID-19 infection, SJP-001 for alcohol hangover prevention, and SJP-005 for opioid withdrawal, among others. These products are designed for various end users, ranging from patients suffering from chronic pain and inflammation to individuals experiencing the adverse effects of alcohol. Sen-Jam Pharmaceutical generates revenue through a combination of direct sales and strategic partnerships. The company engages in business-to-business transactions with healthcare providers, hospitals, and pharmacies, facilitating access to its products for end consumers.

  The company intends to use the January 2025 funding to advance its research and development in collaboration with Novotech. Plans are in place to launch new products targeting various inflammation-related conditions within the next 12 months, further expanding their portfolio. Additionally, Sen-Jam aims to enter new markets, focusing on Europe and Asia, with specific launches anticipated by the end of 2025.